What lowers cholesterol naturally, and when are statins worth it?

Why LDL is the target

LDL particles carry cholesterol into artery walls. Genetic studies, cohort studies and trials together show that LDL causes atherosclerotic heart disease, and that risk falls in proportion to how far, and for how long, LDL is lowered⁶.

Food steps, with the amounts trials used

• Soluble fiber. At least 3 g a day of oat beta-glucan lowered LDL by 0.25 mmol/L (about 10 mg/dL) across 28 trials⁷.
• The "portfolio" pattern. The trial diet contained, per 1,000 kcal, about 1 g of plant sterols, 21 g of soy protein, 10 g of viscous fiber and 14 g of almonds. For a 2,000 kcal day that is roughly 2 g, 43 g, 20 g and 28 g⁸. See plant sterols for sources.
• Less saturated fat. Trials of two years or more that cut saturated fat, replacing it with polyunsaturated fat or carbohydrate, found fewer cardiovascular events².

Red yeast rice is a drug in food's clothing

It contains monacolin K, which is lovastatin. Across 12 commercial products it ranged from 0.10 to 10.09 mg per capsule, and four contained citrinin, a toxin that harmed kidneys in animals⁹. See red yeast rice.

When a statin is worth it

Statins pay off most when your absolute risk is high:

• You have had a heart attack, stroke or stent. Your absolute risk is high, and across 26 trials each 1 mmol/L fall in LDL cut major vascular events by about a fifth in every type of patient studied³.
• No heart disease, but age 40 to 75 with a risk factor (high cholesterol, diabetes, high blood pressure or smoking). A 10-year risk of 10 percent or more earns a recommendation; at 7.5 to under 10 percent a statin is offered selectively⁴.
• Very high cholesterol or early heart disease in the family. Familial hypercholesterolemia usually needs a statin plus diet⁵.
• Unsure? A coronary calcium scan can break a tie. In one cohort of 13,644 people, statin users had fewer events if calcium was present, but not if the score was zero¹⁰.

Side effects are real but smaller than feared. In large trials most muscle complaints among statin users were not caused by the statin, and diabetes risk rose slightly^11,12. Pair medication with food, not instead of it, and never stop a prescribed statin without your prescriber. For the wider picture, see what really lowers heart disease risk.

Does LDL cause heart disease?

A European Atherosclerosis Society consensus statement pooled over 200 prospective cohorts, Mendelian randomization studies (natural experiments based on gene variants) and randomized trials, with more than 2 million participants and over 150,000 cardiovascular events. All showed a dose-dependent, log-linear link between LDL exposure and atherosclerotic disease. Any way of lowering LDL particles should lower risk in proportion to the size and duration of the fall, provided there are no harmful off-target effects⁶.

What statins achieve

The Cholesterol Treatment Trialists pooled individual data from 26 randomized trials (170,000 participants, median follow-up about 5 years). Per 1 mmol/L (about 39 mg/dL) fall in LDL, major vascular events fell by 22 percent (rate ratio 0.78, 95% CI 0.76 to 0.80) and all-cause mortality by 10 percent (0.90, 0.87 to 0.93), with no effect on cancer incidence (1.00, 0.96 to 1.04)³. For people without heart disease, the US Preventive Services Task Force judged the net benefit at least moderate at a 10-year risk of 10 percent or more, at least small at 7.5 to under 10 percent, and the evidence insufficient from age 76⁴.

What food trials achieve

In Jenkins' randomized trial, 46 adults with high cholesterol spent one month on a very-low-saturated-fat control diet (n=16), the same diet plus lovastatin 20 mg (n=14), or the portfolio diet (n=16). LDL fell 8.0, 30.9 and 28.6 percent, and C-reactive protein fell 10.0, 33.3 and 28.2 percent; the portfolio and statin groups did not differ significantly⁸. That trial was small and short. A pooled analysis of 7 trial comparisons in 439 people found a smaller LDL fall of about 17 percent (0.73 mmol/L, 95% CI 0.56 to 0.89) on top of a low-saturated-fat diet, with no change in HDL or weight; certainty was graded high for LDL¹. A meta-analysis of 28 trials found that 3 g or more of oat beta-glucan lowered LDL by 0.25 mmol/L (0.20 to 0.30), with no effect on HDL or triglycerides and a bigger effect at higher starting LDL⁷.

A Cochrane review of 15 trials (about 56,700 participants, each at least two years) found that cutting saturated fat reduced combined cardiovascular events by 17 percent (risk ratio 0.83, 95% CI 0.70 to 0.98; moderate-quality evidence). About 56 people had to cut saturated fat for roughly four years to prevent one event in primary prevention².

Null and conflicting results

The same Cochrane review found little or no effect of cutting saturated fat on all-cause mortality (risk ratio 0.96, 0.90 to 1.03) or cardiovascular deaths (0.95, 0.80 to 1.12)². None of the fiber, sterol or portfolio trials above measured heart attacks or strokes; they measured LDL, a marker.

On statins, a pooled analysis of 19 placebo-controlled trials (123,940 participants) found muscle pain or weakness reported by 27.1 percent on a statin and 26.6 percent on placebo. The excess appeared in year 1 only (rate ratio 1.07, 1.04 to 1.10; 11 extra events per 1,000 person-years), so about one in 15 muscle reports by statin users was due to the drug¹¹. Statins did raise diabetes risk slightly across 13 trials (91,140 participants; odds ratio 1.09, 1.02 to 1.17), about one extra case per 255 people treated for four years¹².

Tools for borderline decisions

In 13,644 people without heart disease followed for a median 9.4 years, statin use was linked to fewer major events when coronary calcium was present (adjusted subhazard ratio 0.76, 0.60 to 0.95) but not when the score was zero (1.00, 0.79 to 1.27). The number needed to treat over 10 years ranged from 100 (score 1 to 100) to 12 (score above 100). It was an observational, single-center study, so confounding is possible¹⁰. For familial hypercholesterolemia, a European consensus advises screening when adult total cholesterol is 310 mg/dL (8 mmol/L) or more, or with premature heart disease or tendon xanthomas, and treating with the maximal potent statin dose, adding ezetimibe or bile acid resins as needed⁵.

Bottom line

Confidence is fairly high (4 of 5). Statin benefit is established by pooled randomized trials³, and food steps reliably lower LDL^1,7,8, with fewer cardiovascular events when saturated fat is cut². The food trials measured cholesterol rather than heart attacks, so the best plan combines both approaches, guided by your absolute risk⁴.